Analysguiden: Clear Focus on Increased Shareholder Value
As expected, Redwood Pharma reported no sales during Q1, and the operating result was SEK -4.3 million. Analysguiden reiterate their SEK 14 target pricce.Continued Development of RP101 and RP501 As expected, Redwood Pharma reported no sales during Q1, and the operating result was SEK -4.3 million (-4.4). In connection with the transfer of the company’s listing to Nasdaq First North, a successful rights issue was carried out which gave the company a cash position of SEK 28 million. To maximize the value of RP101 for dry eye disease (DED) in post-menopausal women, Redwood Pharma explores